Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8196334 | 0.79 | CYP2D6 (0.36) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| SCHEMBL11088915 | 0.76 | ALDH1A1 (0.43) | LMNACYP2D6CYP2C19RAB9ANPSR1 | |
| SCHEMBL10591727 | 0.74 | LMNA (0.40) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| SCHEMBL10597175 | 0.73 | CYP2D6 (0.46) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| SCHEMBL9408950 | 0.72 | SMN1; SMN2 (0.38) | LMNACYP2D6CYP2C19RAB9AKMT2A | |
| SCHEMBL28185448 | 0.72 | KDM4E (0.36) | LMNAMAPT | |
| SCHEMBL28184771 | 0.72 | MAPT (0.32) | HTTMAPT | |
| SCHEMBL8207622 | 0.71 | CYP2D6 (0.42) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| SCHEMBL10854694 | 0.70 | KMT2A (0.47) | LMNACYP2D6CYP2C19RAB9ANPSR1 | |
| SCHEMBL7414724 | 0.69 | KCNN4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| EP-4460301-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2024-11-13 | — | — | EP | claimed |
| US-12091385-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-09-17 | — | — | US | claimed |
| EP-3720493-B1 | COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES | UNIV KOELN (DE) | 2024-07-24 | — | — | EP | claimed |
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2024-02-29 | — | — | US | claimed |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-01-16 | — | — | US | claimed |
| WO-2023131576-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | claimed |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | Rushi Biotech (Hangzhou) Co., Ltd (CN) | 2023-06-22 | — | — | US | claimed |
| EP-1888060-A2 | NK-B INHIBITORS FOR THE TREATMENT OF MUSCULAR DYSTROPHY | A. T. Still University of Health Sciences (US) | 2008-02-20 | — | — | EP | claimed |
| US-20060280812-A1 | Compositions and methods for the treatment of muscular dystrophy | A.T. STILL UNIVERSITY OF HEATH SCIENCES | 2006-12-14 | — | — | US | claimed |
| WO-2006127930-A2 | NK-B INHIBITORS FOR THE TREATMENT OF MUSCULAR DYSTROPHY | A. T. STILL UNIVERSITY OF HEALTH SCIENCES (US) | 2006-11-30 | — | — | WO | claimed |
| US-20260014265-A1 | TRIPLE-PAYLOAD ANTIBODY-DRUG CONJUGATES (ADCs) | ARARIS BIOTECH AG (CH) | 2026-01-15 | — | — | US | disclosed |
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | disclosed |
| US-20250082774-A1 | PEPTIDE LINKERS COMPRISING TWO OR MORE PAYLOADS | ARARIS BIOTECH AG (CH) | 2025-03-13 | — | — | US | disclosed |
| US-20250049943-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2025-02-13 | — | — | US | disclosed |
| EP-0655057-A1 | CYANOGUANIDINES AS POTASSIUM CHANNEL BLOCKERS. | UPJOHN CO (US) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994029280-A1 | PYRIMIDINE CYANOGUANIDINES AS K-CHANNEL BLOCKERS | THE UPJOHN COMPANY (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994004499-A1 | CYANOGUANIDINES AS POTASSIUM CHANNEL BLOCKERS | THE UPJOHN COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994004500-A1 | CYANOGUANIDINES AS POTASSIUM CHANNEL BLOCKERS | THE UPJOHN COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014265-A1 | TRIPLE-PAYLOAD ANTIBODY-DRUG CONJUGATES (ADCs) | TOP2A, TOP1, TOP2B | LMNA 145/4885CYP2D6 3808/4885CYP2C19 2915/4885 |
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNMT | LMNA 2359/4885CYP2D6 863/4885CYP2C19 1130/4885 |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | NAMPT, NAPRT, NNT | LMNA 2314/4885CYP2D6 822/4885CYP2C19 1003/4885 |
| US-12091385-B2 | Pyridinylcyanoguanidine derivative and use thereof | NAMPT, NAPRT, NNT | LMNA 2314/4885CYP2D6 822/4885CYP2C19 1003/4885 |
| US-20250082774-A1 | PEPTIDE LINKERS COMPRISING TWO OR MORE PAYLOADS | DNPEP, VIP, LNPEP | LMNA 2900/4885CYP2D6 4756/4885CYP2C19 4817/4885 |
| US-20250049943-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | TGM1, TGM3, PRMT3 | LMNA 3084/4885CYP2D6 3751/4885CYP2C19 4249/4885 |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNT | LMNA 2314/4885CYP2D6 822/4885CYP2C19 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.